(Q36436240)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

review article

1 reference

title

Advances in oral therapy for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Gareth J Morgan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Biju Krishnan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Faith E Davies

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

18 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

316-325

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

A study of quality of life in cancer patients receiving palliative chemotherapy

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

On the receiving end--patient perception of the side-effects of cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Patient preferences for oral versus intravenous palliative chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Answering patients' needs: oral alternatives to intravenous therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

1 reference

7 January 2021

Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Molecular mechanisms of novel therapeutic approaches for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

VAD-based regimens as primary treatment for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Recent advances in the management of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

1 reference

7 January 2021

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

High-dose glucocorticoid treatment of resistant myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

High-dose dexamethasone for refractory or relapsing multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

A randomized study (WOS MM1) comparing the oral regime Z-Dex (idarubicin and dexamethasone) with vincristine, adriamycin and dexamethasone as induction therapy for newly diagnosed patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide as initial therapy for early-stage myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

The evolution of thalidomide and its IMiD derivatives as anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide as a novel therapeutic agent: new uses for an old product

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Thalidomide and dexamethasone for resistant multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Chemoresistant myeloma: phase II clinical study with low-dose thalidomide plus high-dose dexamethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

The role of immunomodulatory drugs in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Ras oncogene mutation in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Proteasome inhibition in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2806%2970657-X

7 January 2021

10.1016/S1470-2045(06)70657-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16574547%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference